
Shares of Avidity Biosciences Inc (NASDAQ:RNA) rose sharply in pre-market trading after the company agreed to be acquired by Novartis AG (NYSE:NVS).
Holders of Avidity common stock will receive $72.00 per share in cash at closing, representing a premium of around 46% over Avidity’s closing share price on Oct. 24.